Concord Medical Services (CCM) AI Stock Analysis

• Market Cap: $17.37M
• Dividend Yield: N/A
• Average Volume (3M): 9.22K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.27
• Revenue Growth: -25.83%
• EPS Growth: 21.68%
• Country: US
• Employees: 727
• Sector: Healthcare
• Sector Strength: 62
• Industry: Medical - Care Facilities
• EPS (TTM): -12.04
• Shares Outstanding: 2,815,458
• 10 Day Avg. Volume: 10,173
• 30 Day Avg. Volume: 9,217
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.22
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

The overall stock score for Concord Medical Services is low, primarily due to significant financial instability marked by negative profit margins, high leverage, and poor cash flow. Technical analysis shows mixed signals with potential for short-term stability but overall bearish trends. Valuation metrics are weak, with a negative P/E ratio and no dividend, further diminishing the stock's attractiveness.

Concord Medical Services Business Overview & Revenue Model

Company Description

Concord Medical Services (CCM) is a China-based healthcare company that operates in the medical services sector. It specializes in providing radiotherapy and diagnostic imaging services, along with operating a network of cancer hospitals and specialty clinics. The company's core services include advanced radiotherapy treatments and comprehensive diagnostic imaging solutions, which are essential for cancer diagnosis and treatment planning.

How the Company Makes Money

Concord Medical Services generates revenue primarily through the provision of medical services, including radiotherapy and diagnostic imaging. The company operates a network of cancer hospitals and specialty clinics, where it offers these services directly to patients. Revenue streams include patient fees for diagnostic and treatment services, as well as potential partnerships with healthcare providers and insurance companies that facilitate patient access to their services. Additionally, the company may derive income from collaborations or joint ventures with other healthcare entities, which could enhance service offerings and expand their reach in the medical services market.

Concord Medical Services Financial Statement Overview

Summary

Concord Medical Services is facing significant financial difficulties, with poor profitability and high leverage. Despite some revenue growth, the company's negative equity and cash flow issues highlight substantial financial instability. Immediate focus on improving profitability and reducing debt is crucial for future sustainability.

Income Statement

The company consistently reports negative gross and net profit margins, indicating a challenging profitability environment. Revenue has shown some growth, evident from the increase from 2022 to 2023, but the overall financial performance remains weak with negative EBIT and EBITDA margins.

Balance Sheet

The balance sheet reflects significant financial instability, with negative stockholders' equity indicating more liabilities than assets. The high debt-to-equity ratio exacerbates the risk profile. Return on equity is not meaningful due to negative equity.

Cash Flow

The company exhibits negative operating and free cash flows, suggesting inefficiencies in cash generation. However, there is a trend of improving free cash flow from 2022 to 2023. The operating cash flow to net income ratio is not favorable, reinforcing cash flow challenges.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
471.70M	537.40M	472.08M	485.63M	223.01M	198.36M
	Gross Profit
-80.78M	-76.61M	-152.41M	-56.90M	13.08M	-15.83M
	EBIT
-874.75M	-462.99M	-525.05M	-458.32M	-316.00M	-437.29M
	EBITDA
-326.79M	-344.16M	-401.86M	-363.86M	-236.72M	-304.85M
	Net Income Common Stockholders
-378.93M	-297.66M	-489.66M	-271.43M	-309.99M	-307.05M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
243.38M	58.14M	158.28M	157.39M	334.26M	74.31M
	Total Assets
6.07B	6.05B	6.00B	6.23B	5.33B	4.30B
	Total Debt
3.21B	3.30B	3.24B	2.73B	2.35B	1.85B
	Net Debt
2.97B	3.24B	3.08B	2.58B	2.02B	1.78B
	Total Liabilities
3.98B	4.31B	3.99B	3.49B	2.93B	2.41B
	Stockholders Equity
-1.88B	-2.12B	-1.86B	-1.37B	-662.96M	-122.76M
Cash Flow		Free Cash Flow
0.00	-392.17M	-600.47M	-1.12B	-734.47M	-896.27M
	Operating Cash Flow
0.00	-276.47M	-216.69M	-359.31M	-229.77M	-195.35M
	Investing Cash Flow
0.00	-47.68M	-118.79M	-565.98M	-533.88M	-1.07B
	Financing Cash Flow
0.00	257.65M	383.09M	642.45M	1.14B	513.27M

Concord Medical Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Negative. The current price of 4.13 is below the 20-day moving average (MA) of 4.25, below the 50-day MA of 4.64, and below the 200-day MA of 6.05, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 49.86 is Neutral, neither overbought nor oversold. The STOCH value of 56.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CCM.

Concord Medical Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMED	65 Neutral	$3.05B	71.41	3.93%	―	5.01%	―
ADUS	64 Neutral	$1.80B	23.59	8.78%	―	9.06%	10.68%
USPH	63 Neutral	$1.10B	39.31	5.75%	2.44%	11.00%	37.38%
VTR	63 Neutral	$31.11B	355.41	0.80%	2.64%	9.48%	―
DVA	62 Neutral	$12.15B	14.36	159.08%	―	5.56%	45.02%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
CCM	36 Underperform	$17.37M	―	14.03%	―	-25.83%	21.68%